Asparkam

General characteristics. Structure:

Contains the ml of solution operating veshchestva:1 magnesium of asparaginate of anhydrous 40 mg (3,37 mg of magnesium), potassium of asparaginate of anhydrous 45,2 mg (10,33 mg of potassium);

auxiliary are veshchestva:sorbit (Е 420), by water for injections.

Pharmacological properties:

Pharmacodynamics. The asparkam has antiarrhytmic properties, fills up deficit of ions of magnesium and potassium. Magnesium activates sodium - potassium ATP-ase therefore intracellular contents of sodium decrease and hit of potassium in a cell increases. At decrease in concentration of sodium in a cell sodium-calcium exchange in unstriated muscles of vessels which conducts to their relaxation is slowed down, potassium ions stimulate synthesis of ATP, a glycogen, proteins, acetylcholine; potassium and magnesium support polarization of cellular membranes. Asparaginate promotes receipt of ions in a cell and takes part in energy balance. The antiarrhytmic effect is implemented thanks to ability of drug to eliminate an imbalance of electrolytes, to reduce excitability and conductivity of a myocardium.

Pharmacokinetics. The pharmacokinetics of drug was not investigated.

Pharmaceutical characteristics:

main physical and chemical properties. Transparent, colourless or with hardly yellowish shade liquid.

Incompatibility. Data are absent.

Indications to use:

 As a part of complex therapy of heart failure, a myocardial infarction, disturbances of a cordial rhythm (preferential ventricular arrhythmias);
for improvement of portability of cardiac glycosides.

Route of administration and doses:

The asparkam, solution for injections, enter only intravenously.

At intravenous drop administration contents of 2-4 ampoules on 5 ml dissolve 5% of solution of glucose in 50-200 ml and enter with a speed of 25 thaws/min. A single dose of the Asparkam – 10-20 ml. If necessary perhaps repeated introduction in 4-6 hours.

At intravenous jet administration (with a speed no more than 5 ml/min.) contents of 2 ampoules on 5 ml are parted in 20 ml of sterile water for injections or 5% of solution of glucose.

Course of treatment – 5 days.

Features of use:

At long use of drug it is necessary to control the level of potassium and magnesium in blood, and also continuous monitoring of data of an ECG is necessary.

Contraindicated bystry intravenous administration of the drug Asparkam. At bystry intravenous administration of drug the hyperpotassemia and a gipermagniyemiya can develop that can bring to the life-threatening patient of arrhythmia.

At bystry intravenous administration of drug development of a dermahemia is possible. It is necessary to take with caution the Asparkam at an atrioventricular block of the I degree.

Ability to influence speed of response at control of motor transport or work with other mechanisms. The asparkam does not influence speed of response at control of motor transport or work with other mechanisms.

Side effects:

At bystry intravenous administration development of symptoms of a hyperpotassemia (nausea, vomiting, diarrhea, paresthesias) and/or gipermagniyemiya (face reddening, a hyporeflexia, spasms, feeling of heat, respiratory depression) is possible.

Interaction with other medicines:

The asparkam improves portability of cardiac glycosides.

Due to the existence in composition of drug of potassium ions at Asparkam drug use with kaliysberegayushchy diuretics, APF inhibitors, beta adrenoblockers, cyclosporine, heparin, NPVS the risk of development of a hyperpotassemia increases (control of level of potassium in a blood plasma is necessary). Anticholinergics reduce an intestines peristaltics.

Drug strengthens negative dromo-and bathmotropic effect of antiarrhytmic medicines.

Drugs of magnesium reduce efficiency of Neomycinum, polymyxin B, tetracycline and streptomycin.

Anesthetics strengthen the oppressing effect of magnesium on TsNS.

At use of the drug Asparkam with atrakuriy, deksametoniy, succinylcholine strengthening of neuromuscular blockade is possible; with calcitriol – increase in level of magnesium in a blood plasma; with drugs of calcium reduction of action of ions of magnesium is observed.

Contraindications:

Hypersensitivity to drug components.
Acute and chronic renal failure.
Oliguria, anury.
Addison's disease.
Hyperpotassemia, gipermagniyemiya.
Atrioventricular block of II-Iiistepeni.
Cardiogenic shock (with a sistolitichesky pressure <90 mm Hg).
Children's age.

Use during pregnancy or feeding by a breast. Use of drug during pregnancy is possible only if the expected advantage for the woman exceeds potential risk for a fruit. In need of use of drug in the period of a lactation feeding by a breast is recommended to be suspended.

Children. Data on use of drug for treatment of children are absent therefore drug is not used in pediatric practice.

Overdose:

At overdose symptoms of a hyperpotassemia and a gipermagniyemiya are observed.

Treatment: drug withdrawal, symptomatic therapy (intravenous administration of solution of Calcii chloridum in a dose on 100 mg a minute), if necessary – a hemodialysis, peritoneal dialysis.

Storage conditions:

Period of validity 2 years. Store in the place protected from light at a temperature from 15 °C to 25 °C. Store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 5 ml in an ampoule; on 10 ampoules in a box. On 5 ml or 10 ml in an ampoule; on 5 ampoules in the blister; on 2 blisters in a pack.